Chemosensitivity of Lung Metastatic High-Grade Synovial Sarcoma

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Synovial sarcoma is a soft tissue sarcoma known for its chemosensitivity and propensity for lung metastasis.
• Lung metastasectomy is a critical intervention for managing metastatic synovial sarcoma.
• The role of adjuvant chemotherapy following lung metastasectomy in high-grade synovial sarcoma (HGSS) remains an area of investigation.

Purpose of the Study:

• To evaluate the efficacy of adjuvant chemotherapy in patients with high-grade synovial sarcoma undergoing their first lung metastasectomy.
• To determine the impact of adjuvant chemotherapy on survival outcomes in this patient population.

Main Methods:

• A retrospective study of 46 HGSS patients who underwent their first lung metastasectomy between 2000 and 2020.
• Patients were divided into two groups: those who received adjuvant chemotherapy (n=24) and those who did not (n=22).
• Survival outcomes, including freedom from SS-specific mortality and disease-free intervals (DFI), were analyzed.

Main Results:

• Freedom from SS-specific mortality at 60 months was significantly higher in the group that did not receive adjuvant chemotherapy (50.0% vs. 20.8%, p=0.01).
• Adjuvant chemotherapy was associated with an increased risk of SS-specific mortality (HR 2.8, p=0.02).
• Factors such as DFI0 ≤ 6 months, female sex, age > 40, and primary tumor > 10 cm were associated with increased mortality risk.

Conclusions:

• Adjuvant chemotherapy offers no discernible survival advantage for HGSS patients following lung metastasectomy.
• The findings suggest that adjuvant chemotherapy may not be beneficial and could potentially be detrimental in this specific clinical context.
• Larger prospective studies are warranted to validate these results and refine treatment strategies for metastatic synovial sarcoma.